GLP-1 Treated Patients with Diabetes Have Raised Risk for Eye Condition
A new study suggests that patients with type 2 diabetes using GLP-1 receptor agonists may have a slightly higher risk of developing ischemic optic neuropathy. While the absolute risk remains low, researchers observed a higher incidence compared to other diabetes medications.
Why it matters
As GLP-1 drugs become widely used for diabetes and weight loss, understanding potential rare side effects is critical for patient safety and clinical decision-making.
A large study of people with type 2 diabetes suggests that those who started treatment with a glucagon‑like peptide (GLP)‑1 receptor agonist after diagnosis had slightly increased risk of developing a serious eye condition called ischemic optic neuropathy than people with diabetes treated with other medications.
As reported in the Annals of Internal Medicine , the risk for patients given GLP-1 drugs was about twice that of those given a sodium–glucose cotransporter (SGLT)‑2 inhibitor or a dipeptidyl peptidase (DPP)-4 inhibitor although the absolute risk was still low in all groups.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in